Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Wrap Technologies (WRAP – Research Report), Geron (GERN – Research Report) and Capricor Therapeutics (CAPR – Research Report).
Wrap Technologies (WRAP)
In a report released yesterday, Allen Klee from Maxim Group maintained a Hold rating on Wrap Technologies. The company’s shares closed last Thursday at $2.03, close to its 52-week low of $1.60.
According to TipRanks.com, Klee is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Wrap Technologies with a $2.50 average price target.
Needham analyst Gil Blum reiterated a Buy rating on Geron today and set a price target of $3.00. The company’s shares closed last Thursday at $2.05.
According to TipRanks.com, Blum is a 1-star analyst with an average return of
Currently, the analyst consensus on Geron is a Strong Buy with an average price target of $4.67, an 117.2% upside from current levels. In a report issued on July 28, B.Riley Financial also initiated coverage with a Buy rating on the stock with a $4.00 price target.
Capricor Therapeutics (CAPR)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics yesterday and set a price target of $12.00. The company’s shares closed last Thursday at $5.28.
According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Capricor Therapeutics is a Moderate Buy with an average price target of $15.00, which is a 212.5% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on WRAP:
- Form 8.3 – Emis Group Plc
- Venus Concept Announces Second Quarter of Fiscal Year 2022 Financial Results; Updates Fiscal Year 2022 Revenue Guidance
- UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates
- The Honest Company Reports Second Quarter 2022 Results
- Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update